Production & Sales

Knight Therapeutics to acquire Latin American pharma firm Biotoscana

Knight Therapeutics plans to acquire Brazilian pharma company Biotoscana Investments (GBT) for a price of around BRL1.16bn ($281m), which includes the latter’s financial debt.

Sartorius Stedim to buy certain life science businesses of Danaher for $750m

Sartorius Stedim Biotech has agreed to acquire some of the life science businesses of US conglomerate Danaher for around $750m.

Bavarian Nordic to buy GSK’s rabies and tick-borne encephalitis vaccines

Denmark-based Bavarian Nordic has signed an agreement to acquire rabies and tick-borne encephalitis (TBE) vaccines from GlaxoSmithKline in a deal valued at around €796m ($888m).

TriPharm Services announces creation of pharmaceutical manufacturing center

TriPharm Services, a new contract development and manufacturing organization (CDMO), is commissioning a new specialized manufacturing operation utilizing the latest isolator manufacturing equipment.

Sun Pharma launches Drizalma Sprinkle in US

Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries has launched Drizalma Sprinkle (duloxetine delayed-release capsules) in the US for oral use.

Acino to buy Takeda’s select OTC and prescription pharmaceutical assets for $200m

Swiss pharmaceutical company Acino has agreed to acquire Takeda’s select over-the-counter (OTC) and prescription pharmaceutical assets in multiple Near East, Middle East and Africa (NEMEA) countries for a total value of more than $200m.

Thermo Fisher launches IonicX XRF Analyzer to identity ionic salts

Thermo Fisher Scientific has launched a new handheld X-ray fluorescence analyser called IonicX XRF Analyzer to help pharmaceutical and biopharmaceutical manufacturers to verify the identity of ionic salts in warehouses within seconds.

Kyowa Kirin launches NOURIANZ in US for treatment of Parkinson’s disease “Off” episodes

Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes.

Sun Pharma launches CEQUA for treatment of dry eye disease in US

Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has commercialised CEQUA (cyclosporine ophthalmic solution) 0.09% in the US.